Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has received approval for Filspari, increasing the probability of success for the FSGS indication to 100%, leading to a revised DCF-derived valuation estimate. The addressable treatment population for Filspari has expanded to over 30,000 patients in FSGS, reflecting significant growth potential in tandem with a projected revenue increase from ~$2 million quarterly to ~$26 million by Q4 2026, supported by an anticipated faster initial ramp-up due to existing commercial infrastructure from the IgAN launch. Management estimates that with the combined addressable patients across FSGS and IgAN exceeding 100,000, peak sales potential could exceed $3 billion annually, bolstering the long-term growth outlook for the company.

Bears say

Travere Therapeutics Inc faces significant risks that could hinder its financial performance and negatively impact its stock outlook. Potential delays or failures in the commercialization of its products, such as Filspari and pegtibatinase, may reduce sales potential and affect the company's overall valuation. Additionally, challenges in securing necessary funding for clinical trials and product development, coupled with the possibility of market access constraints, pose further threats to Travere's ability to execute its business strategy effectively.

Travere Therapeutics (TVTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 11 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.